z-logo
open-access-imgOpen Access
Synthesis and mechanisms of action of novel harmine derivatives as potential antitumor agents
Author(s) -
Xiaofei Zhang,
Rongqin Sun,
Yifan Jia,
Chen Qing,
Rongfu Tu,
KeKe Li,
Xiaodong Zhang,
Ran Du,
Rihui Cao
Publication year - 2016
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/srep33204
Subject(s) - apoptosis , protein kinase b , chemistry , pi3k/akt/mtor pathway , pharmacology , cancer research , reactive oxygen species , cancer cell , cell culture , parthenolide , cancer , ly294002 , biochemistry , biology , medicine , genetics
A series of novel harmine derivatives bearing a benzylindine substituent in position-1 of β-carboline ring were synthesized and evaluated as antitumor agents. The N2-benzylated β-carboline derivatives 3a–g represented the most interesting anticancer activities and compound 3c was found to be the most active agent to diverse cancer cell lines such as gastric carcinoma, melanoma and colorectal cancer. Notably, compound 3c showed low toxicity to normal cells. The treatment significantly induced cell apoptosis. Mechanistically, PI3K/AKT signaling pathway mediated compound 3c-induced apoptosis. Compound 3c inhibited phosphorylation of AKT and promoted the production of reactive oxygen species (ROS). The ROS scavenger, LNAC and GSH, could disturb the effect of compound 3c induced apoptosis and PI3K activity inhibitor LY294002 synergistically enhanced compound 3c efficacy. Moreover, the results from nude mice xenograft model showed that compound 3c treatment effectively inhibited tumor growth and decreased tumor weight. Collectively, our results demonstrated that compound 3c exerts apoptotic effect in cancer cells via suppression of phosphorylated AKT and evocation of ROS generation, which suggested that compound 3c might be served as a promising therapeutic agent for cancer treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here